Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 210-214

  Kang, Heeseok ^a   Kim, Tae Joong ^b   Lee, Yoo Young ^b   Choi, Chel Hun ^b   Lee, Jeong Won ^b   Bae, Duk Soo ^b   Kim, Byoung Gie ^b  

^a Good Morning Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Carboplatin; Ovarian neoplasms; Response rate; Topotecan; Toxicity

Indexed keywords

CARBOPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RAMOSETRON; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATOCHEZIA; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SURVIVAL RATE; TOPOTECAN;

EID: 67549110751     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.016     Document Type: Article

References (17)

1. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
2. Coleman R.L. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist 7 Suppl 5 (2002) 46-55
3. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14 (1996) 3056-3061
4. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15 (1997) 2183-2193
5. van der Zee A.G., Hollema H., de Jong S., Boonstra H., Gouw A., Willemse P.H., et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 51 (1991) 5915-5920
6. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 86 (1994) 1517-1524
7. Lee Y.S., and Lee T.H. Effect of topotecan in combination with other antitumor drugs in vitro. KJGOC 11 (2000) 83
8. Bowman A.R.T., Ross G., Wheatley A., and Smyth J.F. Reverse-schedule topotecan and carboplatin in relapsed ovarian cancer: a phase I/II doseranging study. ECCO (1999) 10
9. Gordon A.D.K., Hancock M., Messing M., Matthews C.M., and Teneriello M. Phase I study of topotecan (T) with carboplatin (C) alternating with paclitaxel (P) via 3-hour infusion with carboplatin (C) in treatment of newly diagnosed ovarian cancer (OC). Eur. J. Cancer 35 (1999) S237
10. de Jonge M.J., Loos W.J., Gelderblom H., Planting A.S., van der Burg M.E., Sparreboom A., et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J. Clin. Oncol. 18 (2000) 2104-2115
11. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., and Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79 (2000) 116-119
12. Bowman A., Rye T., Ross G., Wheatley A., and Smyth J.F. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. J. Clin. Oncol. 19 (2001) 3255-3259
13. National Cancer Institute: Guidelines for Reporting Adverse Reactions. Bethesda, MD. Division of Cancer Treatment, National Cancer Institute. 1988.
14. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
15. Bolis G., Scarfone G., Sciatta C., Polverino G.P., Rosa C., Guarnerio P., et al. A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol. Oncol. 83 (2001) 477-480
16. Rose P.G., Smrekar M., Haba P., Visser C., and Beeler J.F. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol. Oncol. 99 (2005) 714-719
17. Kang H., Kim T.J., Choi C.H., Lee J.W., Lee J.H., Bae D.S., et al. Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer (in press). J. Korea Med. Sci. (2009) 24